Poly(D,L-lactic-co-glycolic acid) nanoencapsulation reduces erlotinib-Induced subacute toxicity in rat
Autor(a) principal: | |
---|---|
Data de Publicação: | 2009 |
Outros Autores: | , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | http://hdl.handle.net/1822/10498 |
Resumo: | Erlotinib-HCl is a quinazoline derivative used as a drug in the therapy of non-small-cell lung cancer. The present study was conducted to compare the subacute toxicity induced by Erlotinib-HCl delivered to rats as nanoparticles and as free drug. Wistar rats were orally administered with a daily dosage of 200 mg kg−1 Erlotinib-HCl either as free drug or as Poly(D,L-lactic-co-glycolic acid) (PLGA) encapsulated nanoparticles. After four weeks of treatment, the animals were analyzed for toxicological changes. Although nanoparticulate form of the drug did not induce any toxicity, free drug significantly reduced the levels of white blood cells (WBC), red blood cells (RBC) and haemoglobin, while increasing the levels of neutrophils and corpuscular haemoglobin. Moreover, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels were significantly increased in the animals administered with free drug. Histopathological studies confirmed significant damage to the internal organs of animals treated with free drug. Whereas, the internal organs of animals treated with the drug encapsulated in PLGA nanoparticles were more or less similar to the healthy organs. Our results show that Erlotinib-HCl delivered in the form of nanoparticles has less toxic effect than the free drug in experimental rats. |
id |
RCAP_5452d94debcee76d631b3baa2548ab34 |
---|---|
oai_identifier_str |
oai:repositorium.sdum.uminho.pt:1822/10498 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
Poly(D,L-lactic-co-glycolic acid) nanoencapsulation reduces erlotinib-Induced subacute toxicity in ratErlotinib-HClNon-small-cell lung cancerPLGA nanoparticleSubacute toxicityErlotinib-HCIScience & TechnologyErlotinib-HCl is a quinazoline derivative used as a drug in the therapy of non-small-cell lung cancer. The present study was conducted to compare the subacute toxicity induced by Erlotinib-HCl delivered to rats as nanoparticles and as free drug. Wistar rats were orally administered with a daily dosage of 200 mg kg−1 Erlotinib-HCl either as free drug or as Poly(D,L-lactic-co-glycolic acid) (PLGA) encapsulated nanoparticles. After four weeks of treatment, the animals were analyzed for toxicological changes. Although nanoparticulate form of the drug did not induce any toxicity, free drug significantly reduced the levels of white blood cells (WBC), red blood cells (RBC) and haemoglobin, while increasing the levels of neutrophils and corpuscular haemoglobin. Moreover, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels were significantly increased in the animals administered with free drug. Histopathological studies confirmed significant damage to the internal organs of animals treated with free drug. Whereas, the internal organs of animals treated with the drug encapsulated in PLGA nanoparticles were more or less similar to the healthy organs. Our results show that Erlotinib-HCl delivered in the form of nanoparticles has less toxic effect than the free drug in experimental rats.American Scientific PublishersUniversidade do MinhoGregory, MarslinSheeba, Caroline J.Kalaichelvan, V. K.Manavalan, R.Reddy, NeelakantaGregory, Franklin20092009-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/1822/10498eng"Journal of Biomedical Nanotechnology". ISSN 1550-7033. 5:5 (2009) 464-471.1550-703310.1166/jbn.2009.107520201419info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-07-21T12:45:34Zoai:repositorium.sdum.uminho.pt:1822/10498Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T19:43:25.657578Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
Poly(D,L-lactic-co-glycolic acid) nanoencapsulation reduces erlotinib-Induced subacute toxicity in rat |
title |
Poly(D,L-lactic-co-glycolic acid) nanoencapsulation reduces erlotinib-Induced subacute toxicity in rat |
spellingShingle |
Poly(D,L-lactic-co-glycolic acid) nanoencapsulation reduces erlotinib-Induced subacute toxicity in rat Gregory, Marslin Erlotinib-HCl Non-small-cell lung cancer PLGA nanoparticle Subacute toxicity Erlotinib-HCI Science & Technology |
title_short |
Poly(D,L-lactic-co-glycolic acid) nanoencapsulation reduces erlotinib-Induced subacute toxicity in rat |
title_full |
Poly(D,L-lactic-co-glycolic acid) nanoencapsulation reduces erlotinib-Induced subacute toxicity in rat |
title_fullStr |
Poly(D,L-lactic-co-glycolic acid) nanoencapsulation reduces erlotinib-Induced subacute toxicity in rat |
title_full_unstemmed |
Poly(D,L-lactic-co-glycolic acid) nanoencapsulation reduces erlotinib-Induced subacute toxicity in rat |
title_sort |
Poly(D,L-lactic-co-glycolic acid) nanoencapsulation reduces erlotinib-Induced subacute toxicity in rat |
author |
Gregory, Marslin |
author_facet |
Gregory, Marslin Sheeba, Caroline J. Kalaichelvan, V. K. Manavalan, R. Reddy, Neelakanta Gregory, Franklin |
author_role |
author |
author2 |
Sheeba, Caroline J. Kalaichelvan, V. K. Manavalan, R. Reddy, Neelakanta Gregory, Franklin |
author2_role |
author author author author author |
dc.contributor.none.fl_str_mv |
Universidade do Minho |
dc.contributor.author.fl_str_mv |
Gregory, Marslin Sheeba, Caroline J. Kalaichelvan, V. K. Manavalan, R. Reddy, Neelakanta Gregory, Franklin |
dc.subject.por.fl_str_mv |
Erlotinib-HCl Non-small-cell lung cancer PLGA nanoparticle Subacute toxicity Erlotinib-HCI Science & Technology |
topic |
Erlotinib-HCl Non-small-cell lung cancer PLGA nanoparticle Subacute toxicity Erlotinib-HCI Science & Technology |
description |
Erlotinib-HCl is a quinazoline derivative used as a drug in the therapy of non-small-cell lung cancer. The present study was conducted to compare the subacute toxicity induced by Erlotinib-HCl delivered to rats as nanoparticles and as free drug. Wistar rats were orally administered with a daily dosage of 200 mg kg−1 Erlotinib-HCl either as free drug or as Poly(D,L-lactic-co-glycolic acid) (PLGA) encapsulated nanoparticles. After four weeks of treatment, the animals were analyzed for toxicological changes. Although nanoparticulate form of the drug did not induce any toxicity, free drug significantly reduced the levels of white blood cells (WBC), red blood cells (RBC) and haemoglobin, while increasing the levels of neutrophils and corpuscular haemoglobin. Moreover, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels were significantly increased in the animals administered with free drug. Histopathological studies confirmed significant damage to the internal organs of animals treated with free drug. Whereas, the internal organs of animals treated with the drug encapsulated in PLGA nanoparticles were more or less similar to the healthy organs. Our results show that Erlotinib-HCl delivered in the form of nanoparticles has less toxic effect than the free drug in experimental rats. |
publishDate |
2009 |
dc.date.none.fl_str_mv |
2009 2009-01-01T00:00:00Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/1822/10498 |
url |
http://hdl.handle.net/1822/10498 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
"Journal of Biomedical Nanotechnology". ISSN 1550-7033. 5:5 (2009) 464-471. 1550-7033 10.1166/jbn.2009.1075 20201419 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
American Scientific Publishers |
publisher.none.fl_str_mv |
American Scientific Publishers |
dc.source.none.fl_str_mv |
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799132990897389568 |